Chronic Graft-Versus-Host Disease (cGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chronic Graft-Versus-Host Disease (cGVHD) Market Outlook
Thelansis’s “Chronic Graft-Versus-Host
Disease (cGVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Chronic Graft-Versus-Host Disease
(cGVHD) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic
Graft-Versus-Host Disease (cGVHD) Overview
Chronic
Graft-Versus-Host Disease (cGVHD) lasts more than three months after
transplantation and is the most common late complication of allogeneic HSCT,
accounting for approximately 25% of pediatric patients. Chronic GVHD is the
primary cause of nonrelapse mortality and morbidity in long-term HSCT
survivors. cGVHD typically manifests with multiorgan pathology and historically
has been defined temporally as GVHD that occurred later than 100 days post-SCT.
Chronic GVHD has a wide prevalence ranging from 6% to 80%, depending on factors
such as donor type, recipient age, and the source of the transplanted
hemopoietic cells. Chronic GVHD is diagnosed by distinguishing it from acute
GVHD, having at least one diagnostic clinical sign of chronic GVHD, or having at
least one distinctive manifestation confirmed by pertinent biopsy or other
relevant tests in the same or another organ, and ruling out other possible
diagnoses. Chronic GVHD symptoms can appear in the skin, oral and gut mucosa,
eyes, lungs, female genitalia, and connective tissue.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment